Anupam Rasayan signs MoU with 3xper Innoventure for new age pharma molecules
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Alembic has a cumulative total of 184 ANDA approvals (159 final approvals and 25 tentative approvals) from USFDA.
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
This innovative product eliminates two manufacturing steps and simplifies equipment setup
GL0034 is a novel, investigational glucagon-like peptide 1 receptor agonist (GLP-1RA) being studied for the treatment of type 2 diabetes and obesity
The product will be produced at the Eugia Pharma Specialities, Unit-I, Medchal, Malkajgiri District, Telangana, India
This partnership will revolutionize Pharmarack's digital infrastructure with Snowflake's single, integrated platform to facilitate advanced analytic
This patent-pending, high-efficiency chromatography media is used for the purification of novel peptide-based pharmaceuticals in the GLP-1 agonist class including type 2 diabetes and obesity treatments
Subscribe To Our Newsletter & Stay Updated